An overview of clinical trials for personalized neoantigen-based peptide vaccines
| Clinical trial number | Phase | Recruitment status | First posted | Locations | Cancer types | Vaccine name | Administration route of the vaccine |
|---|---|---|---|---|---|---|---|
| NCT05741242 | I/II | Enrolling by invitation | 2023.02.23 | United States Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Solid tumors | - | - |
| NCT05475106 | I | Recruiting | 2022.07.26 | Mexico Instituto de Medicina Regenerativa | Neoplasms | - | i.d. |
| NCT05356312 | Available | 2022.05.02 | Germany Zentrum für Humangenetik Tübingen | Malignant glioma | - | - | |
| NCT05307835 | I | Recruiting | 2022.04.01 | China Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Neoantigen Therapeutics Co., Ltd. | Esophagus cancer | iNeo-Vac-P01 | s.c. |
| NCT05269381 | I | Recruiting | 2022.03.08 | United States Mayo Clinic | Advanced solid tumors | PNeoVCA | s.c. |
| NCT05641545 | I | Recruiting | 2022.12.07 | Germany SLK Kliniken Heilbronn GmbH | Renal cell carcinoma (RCC) | IVAC | - |
| NCT05557240 | - | Recruiting | 2022.09.27 | China Shanghai 10th People's Hospital Hangzhou NeoVax Biotechnology Co., Ltd. LiangGao, Shanghai 10th People's Hospital | Glioblastoma | NeoPep | - |
| NCT04998474 | II | Not recruiting | 2021.08.10 | Netherlands Frame Pharmaceuticals B.V. Erasmus Medical Center The Netherlands Cancer Institute University Medical Center Groningen Leiden University Medical Center | NSCLC | FRAME-001 | s.c. |
| NCT04943718 | I | Recruiting | 2021.06.29 | China Xuanwu Hospital, Beijing Beijing Neoantigen Biotechnology Company | Malignant gliomas | - | s.c. |
| NCT04930783 | I | Recruiting | 2021.06.18 | United States Dana-Farber Cancer Institute Celldex Therapeutics | Melanoma | NeoVax | s.c. |
| NCT04864379 | I | Recruiting | 2021.04.28 | China Sir Run Run Shaw Hospital Hangzhou Neoantigen Therapeutics Co., Ltd. | Malignant solid tumor | iNeo-Vac-P01 | i.v. |
| NCT04810910 | I | Recruiting | 2021.03.23 | China Zhejiang Provincial People's Hospital Hangzhou Neoantigen Therapeutics Co., Ltd. | Pancreatic cancer | iNeo-Vac-P01 | s.c. |
| NCT05153304 | I/II | Not yet recruiting | 2021.12.10 | United States Ezra Cohen | Cancer of the gastrointestinal tract | - | - |
| NCT05111353 | I | Recruiting | 2021.11.08 | United States Washington University School of Medicine National Cancer Institute (NCI) Leidos UNICO Foundation | Pancreatic cancer | - | |
| NCT05098210 | I | Recruiting | 2021.10.28 | United States Fred Hutchinson Cancer Center Amazon.com Services LLC | Melanoma breast cancer | i.m. | |
| NCT04799431 | I | Withdrawn | 2021.03.16 | United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Incyte Corporation National Cancer Institute (NCI) | Colon cancer Pancreatic ductal cancer | s.c. | |
| NCT04509167 | I | Completed | 2020.08.11 | Mexico Instituto de Medicina Regenerativa | Neoplasms | i.d. | |
| NCT04487093 | I | Unknown | 2020.07.27 | China First Hospital of Shijiazhuang City Tianjin Hengjia Biotechnology Development Co., Ltd | NSCLC | iNeo-Vac-P01 | s.c. |
| NCT04397926 | I | Unknown | 2020.05.21 | China Sun Yat-sen University Tianjin Hengjia Biotechnology Development Co., Ltd | NSCLC | HJ-N-001 | s.c. |
| NCT04266730 | I | Not yet recruiting | 2020.02.12 | United States UNC Lineberger Comprehensive Cancer Center | Squamous NSCLC HNSCC | PANDA-VAC | s.c. |
| NCT04625205 | I | Recruiting | 2020.11.12 | Belgium/Spain BioNTech US Inc. | Melanoma | NEO-PTC-01 | - |
| NCT04248569 | I | Recruiting | 2020.01.30 | United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb Fibrolamellar Cancer Foundation | FLC | - | |
| NCT04087252 | I | Unknown | 2019.09.12 | China Henan Cancer Hospital | Cancer | i.m. | |
| NCT04072900 | I | Unknown | 2019.08.28 | China Xiangya Hospital of Central South University | Cutaneous melanoma | Neo-Vac-Mn | - |
| NCT04024878 | I | Recruiting | 2019.07.18 | United States Dana-Farber Cancer Institute United States Department of Defense | Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer | NeoVax | s.c. |
| NCT03956056 | I | Terminated | 2019.05.20 | United States Washington University School of Medicine National Institutes of Health (NIH) National Cancer Institute (NCI) | Pancreatic cancer | s.c. | |
| NCT03929029 | I | Recruiting | 2019.04.26 | United States Dana-Farber Cancer Institute National Cancer Institute (NCI) | Melanoma | NeoVax | s.c. |
| NCT04161755 | I | Active, not recruiting | 2019.11.13 | United States Memorial Sloan Kettering Cancer Center Genentech, Inc. | Pancreatic cancer | RO7198457 | - |
| NCT03807102 | I/II | Unknown | 2019.01.16 | China Hunan Province Tumor Hospital Shanghai Houchao Biotechnology Co., Ltd. | Lung cancer | TVATLC01 | - |
| NCT03871790 | - | Completed | 2019.03.12 | Pakistan CENTOGENE GmbH Rostock | CRC Pancreatic cancer | - | |
| NCT03662815 | I | Unknown | 2018.09.07 | China Sir Run Run Shaw Hospital Hangzhou Neoantigen Therapeutics Co., Ltd. | Malignant solid tumor | iNeo-Vac-P01 | s.c. |
| NCT03673020 | I | Completed | 2018.09.17 | United States Agenus Inc. School of Medicine at the University of Miami | Solid Tumor | ASV® AGEN2017 | - |
| NCT03645148 | I | Completed | 2018.08.24 | China Zhejiang Provincial People's Hospital | Pancreatic cancer | iNeo-Vac-P01 | s.c. |
| NCT03633110 | I/II | Completed | 2018.08.16 | United States Genocea Biosciences, Inc. UC San Diego Moores Cancer Center La Jolla | Cutaneous melanoma NSCLC HNSCC Urothelial carcinoma RCC | GEN-009 | s.c. |
| NCT03631043 | I | Recruiting | 2018.08.15 | United States M D Anderson Cancer Center | Smoldering plasma cell myeloma | s.c. | |
| NCT03606967 | II | Recruiting | 2018.07.31 | United States National Cancer Institute (NCI) | Breast carcinoma | s.c. | |
| NCT03597282 | I | Terminated | 2018.07.24 | United States BioNTech US Inc. Apexigen, Inc. | Melanoma | NEO-PV-01 | s.c. |
| NCT03568058 | I | Active, not recruiting | 2018.06.26 | United States University of California, San Diego | Advanced cancer | s.c. | |
| NCT03559413 | I/II | Unknown | 2018.06.18 | Germany University Children's Hospital Tuebingen German Cancer Research Center Universität Tübingen University Hospital Tuebingen | ALL | i.d. | |
| NCT03558945 | I | Recruiting | 2018.06.15 | China Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Pancreatic cancer | s.c. | |
| NCT03552718 | I | Active, not recruiting | 2018.06.12 | United States NantBioScience, Inc. Chan Soon-Shiong Institute for Medicine El Segundo | CRC Breast cancer HNSCC Melanoma NSCLC Pancreatic cancer Liver cancer | YE-NEO-001 | - |
| NCT03422094 | I | Terminated | 2018.02.05 | United States Washington University School of Medicine Bristol-Myers Squibb | Glioblastoma | NeoVax | - |
| NCT03715985 | I/II | Active, not recruiting | 2018.10.23 | Denmark Herlev Hospital | Malignant melanoma NSCLC Bladder urothelial carcinoma | NeoPepVac (EVAX-01-CAF09b) | Intraperitoneal (3 times) + i.m. (3 times) |
| NCT03219450 | I | Recruiting | 2017.07.17 | United States Dana-Farber Cancer Institute Oncovir, Inc. BioNTech SE Merck Sharp & Dohme LLC | CLL | NeoVax | s.c. |
| NCT03166254 | I | Withdrawn | 2017.05.25 | United States Merck Sharp & Dohme LLC Washington University School of Medicine | Lung cancer | NEO-PV-01 | - |
| NCT03068832 | I | Withdrawn | 2017.03.03 | United States Washington University School of Medicine | Brain tumors | - | |
| NCT03361852 | I | Recruiting | 2017.12.05 | United States Dana-Farber Cancer Institute | Follicular lymphoma | Neo Vax | s.c. |
| NCT03380871 | I | Completed | 2017.12.21 | United States BioNTech US Inc. Merck Sharp & Dohme LLC | NSCLC | NEO-PV-01 | s.c. |
| NCT03359239 | I | Completed | 2017.12.02 | United States Matthew Galsky Genentech, Inc. | Urothelial/bladder cancer | PGV001 | - |
| NCT02897765 | I | Completed | 2016.09.13 | United States BioNTech US Inc. Bristol-Myers Squibb | Urinary bladder cancer Transitional cell Carcinoma of the bladder Malignant melanoma NSCLC | NEO-PV-01 | s.c. |
| NCT02992977 | I | Terminated | 2016.12.14 | United States Agenus Inc. | Advanced cancer | AutoSynVax™ | s.c. |
| NCT02950766 | I | Recruiting | 2016.11.01 | United States Dana-Farber Cancer Institute Bristol-Myers Squibb Oncovir, Inc. | RCC | NeoVax | s.c. |
| NCT02510950 | I | Terminated | 2015.07.29 | United States Washington University School of Medicine | Glioblastoma multiforme Astrocytoma | - | |
| NCT02600949 | I | Recruiting | 2015.11.09 | United States M.D. Anderson Cancer Center National Cancer Institute (NCI) | Colorectal adenocarcinoma Pancreatic ductal cancer | - | |
| NCT02287428 | I | Recruiting | 2014.11.10 | United States Dana-Farber Cancer Institute The Ben & Catherine Ivy Foundation Accelerate Brain Cancer Cure Merck Sharp & Dohme LLC National Institutes of Health (NIH) | Glioblastoma | NeoVax | s.c. |
| NCT01970358 | I | Completed | 2013.10.28 | United States Dana-Farber Cancer Institute | Melanoma | NeoVax | s.c. |
RCC, renal cell carcinoma; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; CRC, colorectal cancer; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; i.m., intramuscularly; s.c., subcutaneous.